Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bioengineering
Can-Fite Develops a Blood Test to Predict Patients' Response to the Company Drugs
October 8th, 2007
Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, completed the development of a blood test that determines the mRNA expression levels of the A3 adenosine receptor. The latter is a G protein cell surface receptor, highly expressed in inflammatory and cancer cells and has low expression in normal cells. The Company drugs target with high affinity and selectivity this cell surface receptor. The blood test, which was developed by Can-Fite scientists, requires minute blood quantities and can be analyzed by qualified labs. Company scientists have also found that the blood levels of this receptor reflect its status in the remote...
Source: Biotech Business Week (2007-10-08)
|
